5,000 Shares in GeneDx Holdings Corp. (NASDAQ:WGS) Bought by Mission Wealth Management LP

Mission Wealth Management LP bought a new position in GeneDx Holdings Corp. (NASDAQ:WGS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 5,000 shares of the company’s stock, valued at approximately $384,000.

Several other hedge funds also recently made changes to their positions in the company. Fred Alger Management LLC bought a new position in GeneDx in the 3rd quarter worth $16,731,000. Geode Capital Management LLC raised its holdings in GeneDx by 8.7% in the 3rd quarter. Geode Capital Management LLC now owns 377,631 shares of the company’s stock worth $16,030,000 after purchasing an additional 30,379 shares in the last quarter. State Street Corp raised its holdings in GeneDx by 18.3% in the 3rd quarter. State Street Corp now owns 314,914 shares of the company’s stock worth $13,365,000 after purchasing an additional 48,735 shares in the last quarter. Zweig DiMenna Associates LLC bought a new position in GeneDx in the 4th quarter worth $23,788,000. Finally, Point72 Asset Management L.P. raised its holdings in GeneDx by 87.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 293,671 shares of the company’s stock worth $12,463,000 after purchasing an additional 136,926 shares in the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 1,137 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $76.37, for a total transaction of $86,832.69. Following the transaction, the chief financial officer now owns 24,731 shares in the company, valued at approximately $1,888,706.47. This represents a 4.40 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Katherine Stueland sold 51,420 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $94.48, for a total transaction of $4,858,161.60. Following the transaction, the chief executive officer now owns 1,720 shares in the company, valued at $162,505.60. This represents a 96.76 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 127,321 shares of company stock worth $11,315,903. Company insiders own 27.30% of the company’s stock.

GeneDx Stock Up 6.4 %

NASDAQ:WGS opened at $105.31 on Thursday. The firm’s 50-day moving average price is $82.49 and its 200-day moving average price is $66.82. The company has a market capitalization of $2.96 billion, a PE ratio of -53.73 and a beta of 2.01. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. GeneDx Holdings Corp. has a 1-year low of $7.72 and a 1-year high of $115.60.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.04 by $0.66. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The company had revenue of $95.64 million for the quarter, compared to the consensus estimate of $82.24 million. On average, equities analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Analyst Ratings Changes

WGS has been the subject of several research reports. TD Cowen upped their price objective on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, January 7th. The Goldman Sachs Group upped their target price on shares of GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $72.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.